冬虫夏草和灵芝美国授权专利分析

Analysis of authorized patents of Cordyceps sinensis and Ganoderma lucidum in the United States

为了解其在国际舞台的开发应用现状,通过分析冬虫夏草与灵芝的美国授权专利变化趋势。结果表明:灵芝的美国专利申请早于冬虫夏草,且专利数量也显著较多;灵芝专利在其多糖用于调节免疫活性、抗肿瘤方面相对集中,其次为灵芝孢子开发相关衍生,其他领域相对分散;冬虫夏草专利在其组分用于预防治疗脂肪肝和肝纤维化类疾病及抗骨质疏松等领域较集中,其次为鉴定、培养、杂交类专利;冬虫夏草和灵芝在美国授权专利的申请数量较少,开发与应用仍有较大空间。申请人分析表明,江中药业股份有限公司在冬虫夏草的专利申请具有较领先优势,ACAD SINIC研究院在灵芝专利申请具有领先优势。

Cordyceps sinensis and Ganoderma lucidum are well-known and premium Chinese herbal medicine.In order to understand development and application status of Cordyceps sinensis and Ganoderma lucidum,we conducted a United States granted patent analysis.The results showed that the US patent application of Ganoderma lucidum was earlier than that of Cordyceps sinensis,and the number of patents of Ganoderma lucidum was more than the number of patents of Cordyceps sinensis.The patents of Ganoderma lucidum were specialized in polysaccharides for regulating immune activity and anti-tumor,Ganoderma lucidum spores related derivatives,and other fields were relatively scattered.The patents of Cordyceps sinensis were specialized in the fields of prevention and treatment of fatty liver and hepatic fibrosis diseases and anti-osteoporosis,identification,cultivation,and hybridization.On the whole,Cordyceps sinensis and Ganoderma lucidum have fewer patent applications in the US.Thus,there is still a lot of potential in development and application.The applicant analysis showed that Jiangzhong Pharma Company played a leading role in the patent application of Cordyceps sinensis,and the ACAD SINIC had a leading advantage in the patent application of Ganoderma lucidum.